Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience

Akdaş, Elçin; Adışen, Esra; Öztaş, Murat Orhan; Aksakal, A. Burhan; İlter, Nilsel; Gülekon, Ayla

doi:10.1016/j.abd.2022.06.003

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 Our experiences and evidence from previous studies have shown that in the significant proportion of patients who responded to omalizumab, it is unlikely to discontinue treatment for several years. 5,6 There are observations that patients with CSU often experience unusual emotional stress before disease onset and report symptoms that are worsened by stress. It has also been reported that many patients with CSU exhibit a variety of psychiatric disorders, most commonly anxiety, depression and perceived stress.…”

Section: Introductionmentioning

confidence: 99%

Stressful life events, psychiatric comorbidities and serum neuromediator levels in patients with chronic spontaneous urticaria treated with omalizumab

Akdaş,

Gülekon,

Deveci Bulut

et al. 2024

Allergol Immunopathol

View full text Add to dashboard Cite

Introduction: Many chronic spontaneous urticaria (CSU) patients have highly stressful life events and exhibit psychiatric comorbidities. Emotional stress can cause or exacerbate urticaria symptoms by causing mast cell degranulation via neuromediators. Objectives: To investigate the frequency of stressful life events and compare psychiatric comorbidities and serum neuromediator levels in patients with CSU who responded to omalizumab with healthy controls. Methods: In this cross-sectional study, we included 42 patients with CSU who received at least 6 months of omalizumab treatment and a control group of 42 healthy controls. Stressful life events were evaluated with the Life Events Checklist for DSM-5 (LEC-5). The Depression Anxiety Stress Scale-42 (DASS-42) was used to evaluate depression, anxiety and stress levels. Serum nerve growth factor (NGF), calcitonin gene-related peptide (CGRP) and substance P (SP) levels were measured using the enzyme-linked immunosorbent assay (ELISA) technique. Results: Twenty-six (62%) patients reported at least one stressful life event a median of 3.5 months before the onset of CSU. There were no significant differences in all three variables in the DASS subscales between the patient and control groups. Serum NGF levels were found to be significantly lower in patients with CSU (p<0.001), whereas CGRP levels were found to be significantly higher (p<0.001). There was no significant difference for SP. Conclusions: The psychological status of patients with CSU who benefited from omalizumab was similar to that of healthy controls. Omalizumab may affect stress-related neuromediator levels.

show abstract